Research shows that the type of CHO [the GI] accounts for around 90% of the effect of food on blood glucose. When originally developed, GI was designed to be used in conjunction with CHO exchanges, or the like, to assist people to more evenly distribute their CHO intake throughout the day and to improve BGL control. Nine reasons which support the use of GI in the management of diabetes include:

1.Low GI foods and meals lead to smaller fluctuations in blood glucose levels compared to high GI equivalents.

2.Low GI diets improve glycated haemoglobin as much as many diabetic medications.

3.Low GI diets improve glycated haemoglobin without the risk of having a hypo or other side effect.

4.Low GI diets improve the body’s ability to use insulin.

5.Low GI diets improve the common risks for heart and blood vessel disease.

6.Low GI diets may also improve the ability to lose more body fat and to conserve lean muscle.

7.May also improve one’s ability to lose weight as they assist in feeling fuller for longer.

8.Low GI diets are sustainable.

9.Low GI diets are supported by Diabetes organisations from around the world including Diabetes UK, the European Association for the study of Diabetes, the Canada Diabetes Association and the American Diabetes Association.

To achieve a low GI diet you should include at least one low GI food at each meal or snack. Some good low GI foods are listed below: Pasta, Basmati or Doongara rice, milk, yoghurt, ice cream, sweet potato, carrot, peas, corn and fruit. Gram for gram…sugars do not aggravate blood glucose levels more than most starches That is, most sugars are no worse than most starches with the same amount of Carbohydrate.

Latest News

Updates

Study of Umbilical Cord Blood-Derived Stem Cells for Lupus Therapy

Human umbilical cord blood-derived mensenchymal stem cells (uMSCs) have been found to offer benefits for treating lupus nephritis (LN) when transplanted into mouse models of systemic lupus erythematosus (SLE). SLE is an autoimmune disease with “myriad immune system aberrations” characterised by diverse clinical conditions, including LN, a leading cause of morbidity and mortality for patients with SLE. The beneficial results were reported in a study by Taiwanese researchers published in the current issue of Cell Transplantation (20:2).

According to corresponding author Dr. Oscar K. Lee of the National Yang-Ming University School of Medicine, MSCs have been shown to possess immune-modulatory capabilities and can alleviate immune responses by inhibiting inflammation as well as the function of mature and immature immune system T cells. Seeking to explore the therapeutic effects of uMSCs in treating LN, their study systemic immune diseases closely resembling SLE in humans.

“We found that uMSC transplantation markedly delayed the deterioration of renal function, reduced certain antibody levels, alleviated changes in renal pathology and the development of proteinuria – the presence of excess protein serum in the urine and a sign of renal damage,” said Dr. Lee.

The positive difference in survival rate for mice treated at two months of age compared with mice treated at six months of age, led the researchers to conclude that early uMSC transplantation may be most efficacious. The researchers also deduced that their findings favored the use of allogenic (other-donated) rather than autologous (self-donated) MSCs for SLE treatment, which would make sense with an autoimmune disorder.

“The therapeutic effects demonstrated in this pre-clinical study support further exploration of the possibility of using uMSCs from mismatched donors in LN treatment,” concluded Dr. Lee.

“The ability of uMSCs to reduce inflammation means that they are likely to be of use in the treatment of autoimmune disorders and this study supports that reasoning and, in this case, also advocates the use of non-self cells,” said Dr. David Eve, associate editor of Cell Transplantation and an instructor at the University of South Florida Centre of Excellence for Aging and Brain Repair.